Video Interview: Grünenthal Reveals Plans To Maintain Robust Growth Following Strong 2015
This article was originally published in Scrip
Executive Summary
While other pharma majors have struggled against a number of headwinds, Grünenthal GmbH saw a solid year of growth in 2015 with anticipated revenues of some €1.2bn. Speaking to Informa Pharma Insight's global director of content Mike Ward at the recent Biotech Showcase, Grünenthal's CSO, Dr. Klaus Langner, explains what underpinned this performance as well as discussing the company's plans to expand beyond its core strength in pain management to niche therapeutic fields. Plans include increasing investment in R&D, establishing new partnerships and licensing agreements to bolster the pipeline and existing product portfolios to access assets identified by a four-person innovative medicines unit.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.